Fullintel Logo
  • Solutions
    • Media Intelligence Platform
    • Executive News Briefings
    • Strategic Media Analysis
    • 24/7 Situation Management
  • By Need
    • Enterprise
    • PR Agencies
    • Government Services
  • Resources
    • Blog
    • PR Glossary
    • Newsroom
  • Customers
  • About
Client Login
Contact Us
Request Demo
Blog, Media Monitoring

Top Pharma News in September 2024

October 2, 2024 Angela Dwyer
Pharma Newsletter Banner|Pharma stories volume|Pharma Trending Rank||Sentiment of Neuralink's Blindsight Device|Sentiment of Eli Lily Story

The pharmaceutical industry is undergoing rapid transformation, with continuous advancements in drug development, technologies, and strategic collaborations. This dynamic landscape is shaped by regulatory updates, innovations in treatment, and new opportunities that redefine healthcare. In this newsletter, we cover top news stories that highlight developments, breakthroughs, and effective marketing strategies that are shaping the future of healthcare. As the pharmaceutical sector evolves, Fullintel Hub provides a trusted source of comprehensive insights, offering timely and relevant news to help you stay informed on the latest industry trends.

Top Coverage Highlights the FDA’s Approval of OTC Hearing Aid Software for Apple AirPods, Neuralink Blindsight’s ‘Breakthrough Device’ Recognition, and Eli Lilly’s Launch of Affordable Zepbound Vials

This month’s newsletter covers three healthcare innovations with potential positive societal outcomes: the FDA-approved over-the-counter (OTC) hearing aid software for Apple AirPods Pro, improving hearing care accessibility; Neuralink’s Blindsight brain implant gaining FDA breakthrough status for its progress in restoring vision for the blind; and Eli Lilly’s introduction of more affordable single-use vials of the weight-loss drug Zepbound, enhancing access to obesity treatment.

The hearing aid software for Apple AirPods Pro is the biggest news driver this month in the pharma industry. It garners the most headlines, the most volume, and the most shares making it the top-ranked story in trending coverage. Elon Musk-owned neurotechnology firm Neuralink continues to maintain its media presence with the FDA breakthrough status for Blindsight, a brain implant aimed at restoring sight for the blind. Accessibility of weight-loss drugs continues to capture media attention, with Eli Lilly’s launch of cheaper single-use vials of its popular weight-loss drug Zepbound.

A Break-Down of Recent Trending Stories:

FDA’s Approval of OTC Hearing Aid Software for AirPods Drives High Media Coverage and Engagement

The FDA approved the first over-the-counter (OTC) hearing aid software for Apple AirPods Pro—marking a significant advancement in accessible hearing technology. This approval enables AirPods Pro 2 to function as hearing aids for individuals with mild-to-moderate hearing loss, with personalized settings available through an iPhone and iOS HealthKit. The approval aligns with the FDA’s 2022 initiative to expand access to OTC hearing aids, addressing a major public health issue affecting more than 30 million Americans. This software-based solution offers an innovative alternative to traditional hearing aids, potentially encouraging adoption among individuals hesitant to seek medical intervention. The news gains widespread media coverage and trends on September 13, the day after the approval, reflecting substantial public interest. The story generates the highest social media engagement this month, with positive Facebook reactions, as users are amazed by AirPods’ transformation into hearing aids, merging everyday technology with medical assistance. Media coverage is largely positive, praising the increased accessibility, while slight negativity stems from privacy concerns or doubts about the software’s effectiveness compared to traditional hearing aids.

.

Neuralink Implant Gains Widespread Media Attention and Public Support Following FDA Recognition for Its Vision Restoration Device

Neuralink, Elon Musk’s neurotechnology venture, once again receives favorable media attention after securing FDA breakthrough designation for its Blindsight device. This device aims to restore vision in individuals who have lost sight in both eyes and their optic nerve. The brain implant uses Neuralink’s brain-computer interface technology seeking to restore sight through direct brain stimulation. This development, along with Neuralink’s ongoing PRIME study, represents neurotechnology progress and healthcare innovation. It offers new hope to those with severe vision impairments and underscores the advancements in brain-computer interface technology. The news, which broke on September 17, quickly gains media attention and reaches peak trending status on September 18 and 19. The general reception is favorable, with most social reactions expressing awe. Media coverage is largely positive, with minimal concerns arising from ethical considerations and skepticism regarding long-term safety implications. The story garners the second-highest engagement of 4.4K and is expected to continue generating media buzz in the coming month.

Eli Lilly’s Release Of Lower-Cost Zepbound Vials Keeps the Weight-loss Narrative Afloat, Garnering Notable Coverage

Weight-loss treatment coverage is on the rise in the pharmaceutical media space, with Eli Lilly’s launch of cheaper single-use vials for its weight-loss drug Zepbound making headlines on August 28 and 29. The brand improves access to obesity treatments with more affordable vials, at half the price of its injector pen versions. The new vials, priced at $399 for 2.5 mg and $549 for 5 mg for a four-week supply, are expected to reshape the market. Sold directly through Eli Lilly’s LillyDirect platform, this approach bypasses traditional pharmacies, simplifying the process for patients. Media coverage surrounding this news is predominantly neutral, with most reports maintaining an objective stance, reflecting the challenge of balancing increased accessibility with concerns over widespread drug use and potential misuse. The “Laugh” reactions on social media highlight skepticism that a cheaper version of an expensive drug is still priced at $399-$549 for a four-week supply, as it remains unaffordable for many.

  • event media monitoring
  • event monitoring
  • Media Monitoring
  • Neuralink Blindsight
  • OTC Hearing Aid Software
  • Pharma News
  • PR
  • Public Relations
  • Zepbound Vials
Angela Dwyer
Angela Dwyer

Angela Dwyer is an award-winning, media measurement expert who helps brand improve business results through data-driven, actionable insights.

Post navigation

Previous
Next

Leave a Reply

Your email address will not be published. Required fields are marked *

Search

Categories

  • Blog 175
  • Business 38
  • campaign 1
  • Executive Insights 7
  • Marketing 8
  • Media Monitoring 161
  • News 1
  • Newsroom 14
  • PR Crisis 8
  • PR Lessons 5
  • PR Strategy 3
  • Press Release 8
  • Shows 1
  • Top media outlets 36
  • White paper 4

Recent posts

  • Influencer Marketing_2025
    Influencer Marketing: What Works and What Doesn’t in 2025?
  • Media Monitoring|Media monitoring
    Media Monitoring Mastery: The PR Professional’s Practical Guide
  • Met Gala 2025
    2025 Met Gala: What Brand Storytelling and Silence Can Still Say

Tags

AMEC AMEC Awards Angela Dwyer business intelligence ChatGPT Communications crisis communication Crisis Communications crisis management crisis media monitoring Crisis Monitoring Data and Measurement digital marketing event media monitoring event monitoring influencer marketing influencer monitoring IPRRC Kamala Harris media analysis media intelligence media measurement Media Monitoring media monitoring platform media monitoring service media monitoring services Pharma News PR PR Conferences PR Crisis PredictiveAI™ PR lessons PR measurement PR news PR Research PRSA PRSA ICON PR Tools PR trends Public Relations public relations strategy Sentiment Analysis social listening social media monitoring social media platforms

Related posts

Media Monitoring|Media monitoring
Blog, Executive Insights, Media Monitoring, PR Lessons, PR Strategy

Media Monitoring Mastery: The PR Professional’s Practical Guide

May 9, 2025 Ted Skinner

Let’s Talk About Media Monitoring (and Why It Really Matters) Let’s cut to the chase—you can’t manage what you don’t measure, right? That’s where media monitoring comes in. It’s essentially your ears to the ground, helping you track what’s being said about your brand, competitors, and industry across all sorts of media channels. If you’ve […]

How Labubus, Coca Cola, and PepsiCo had Winning Strategies
Business, Media Monitoring

Tracking Consumer Trends: How Labubus, Coca Cola, and PepsiCo had Winning Strategies

April 24, 2025 Angus Nguyen, Katie Michel

If you’ve scrolled through TikTok or wandered into niche toy stores recently, you’ve probably noticed the growing obsession with blind boxes—sealed packages containing mystery collectible figurines. Brands like Sonny Angels, Labubu, and Pop Mart’s expanding lineup have turned the unboxing experience into a cultural phenomenon, especially among Gen Z and Millennials. But this isn’t just […]

China’s PR Masterclass in the Era of Tariffs and Trade Wars
Business, Media Monitoring

China’s Public Relations Strategy: How Soft Power Shapes Global Influence

April 17, 2025 Angus Nguyen

For a country that’s not exactly known for subtlety in the global narrative game, China’s been playing a PR strategy that’s part spicy, part savage, and all kinds of smart lately. Let’s be real: when the tariff wars kicked off and Western politicians started using China as their go-to punching bag, Beijing could’ve defaulted to […]

Fullintel Logo

Schedule time with a media expert to see a live, one-on-one demo.

  • 1.339.970.8005
  • Book a Demo
  • LinkedIn
  • Facebook
  • X
Solutions
  • Media Intelligence Hub
  • Executive News Briefings
  • Strategic Media Analysis
  • 24/7 Situation Monitoring
By Need
  • Enterprise
  • PR Agency
  • Government
Resources
  • Blog
  • Product Updates
  • Case Studies
Want to receive news and updates?

    © FullIntel, LLC. All Rights Reserved.

    • Terms & Conditions
    • Privacy Policy